Korean Drug names Park Hae-ryong sole CEO after Park Sang-hoon resigns co-CEO role

• Korean Drug named Park Hae-ryong as sole CEO, replacing the co-CEO structure with Park Sang-hoon.
• The change took effect Oct. 1, 2026, following Park Sang-hoon’s resignation as CEO.
• Park Hae-ryong has served as chairman and CEO at Koryo Pharm since April 1982.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korean Drug Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001900105), on October 01, 2026, and is solely responsible for the information contained therein.